C

CRISPR Therapeutics AG
D

CRSP

40.720
USD
0.36
(0.89%)
Market Closed
Volume
110,459
EPS
-5
Div Yield
-
P/E
-15
Market Cap
3,475,593,665
OverviewSignalsIdeasNews
Related Instruments
    B
    BLUE
    -0.69000
    (-7.52%)
    8.49000 USD
    C
    CRIS
    0.03000
    (0.98%)
    3.10000 USD
    E
    EDIT
    -0.01000
    (-0.75%)
    1.32000 USD
    F
    FATE
    0.04000
    (2.42%)
    1.69000 USD
    GILD
    GILD
    1.460
    (1.60%)
    92.570 USD
    N
    NTLA
    0.120
    (0.99%)
    12.190 USD
    PFE
    PFE
    0.595
    (2.31%)
    26.360 USD
    REGN
    REGN
    -5.64
    (-0.80%)
    702.60 USD
    S
    SGMO
    0.17500
    (7.56%)
    2.49000 USD
    VRTX
    VRTX
    0.58
    (0.15%)
    397.15 USD
    More
News

Title: CRISPR Therapeutics AG

Sector: Healthcare
Industry: Biotechnology
Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), whichis a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.